International Flavors & Fragrances Inc. Q4 FY2025 earnings call

Key managerial messages include: Portfolio optimization with divestitures of Pharma Solutions, nitrocellulose, and René Laurent businesses, and launch of sale process for Food Ingredients. Reinvestment in R&D, commercial capabilities, and manufacturing capacity. Balance sheet strength with net debt to credit adjusted EBITDA at 2.6. Innovation investments across segments, including in Scent, Health and Bioscience, and Taste. Progress in each segment's performance, such as Taste's sales growth and EBITDA increase, Health and Biosciences' sales and EBITDA growth, and Scent's sales growth despite Fragrance Ingredients challenges.

In 2025, Taste segment saw sales increase 2% to $588,000,000 with EBITDA of $94,000,000, a 17% increase. Food Ingredients had sales of $802,000,000, down 4%, but achieved 10% EBITDA growth and 150 basis points of EBITDA margin expansion. Health and Biosciences segment had sales of $589,000,000, up 5%, and EBITDA of $155,000,000, a 20% increase. Scent segment had sales of $610,000,000, up 4%, with EBITDA of $106,000,000, up 1%, but Fragrance Ingredients were under pressure due to market softness and price competition.

For 2026, expected sales in the range of $10,500,000,000 to $10,800,000,000 representing comparable currency-neutral growth of 1% to 4%. Expected full year 2026 EBITDA between $2,050,000,000 and $2,150,000,000 representing comparable currency-neutral growth of 3% to 8%. Focus on volume growth, productivity gains, and selective reinvestment in high-value businesses. FX expected to have approximately one percentage point positive impact to sales and negligible impact on EBITDA.

Macroeconomic uncertainty persisting through 2026, geopolitical volatility affecting market conditions, market softness and price competition impacting Fragrance Ingredients, potential destocking risks, and uncertainties related to the sale process of the Food Ingredients business.

Q: About price and volume assumptions in 2026 A: Growth expected to be volume-driven. Incremental margins are roughly 30% to 35% on volumes depending on the business segment Q: Color on assumptions behind top and bottom end of 1% to 4% currency-neutral sales outlook A: Guidance assumes current market conditions. To achieve higher end, need broader improvement in end market volumes; lower end relates to more subdued market growth. Q4 2025 top line better than expected due to new wins Q: Comment on early interest in Food Ingredients sale and proceeds deployment A: Had early interest from strategics and private equity, launched sale process two weeks ago. Proceeds to be used for share buybacks to offset dilution and pay down debt to stay below 3.0 debt to EBITDA ratio Q: Price in Scent segment and mix impact A: Pricing flat in quarter. Fine Fragrance (highest margin) outperformed Consumer Fragrance, but overall pricing was flat due to input cost lag and market dynamics Q: Health and Biosciences margin uplift and outlook A: Fourth quarter margin uplift due to volume growth and productivity. Health business flattening in first half 2026 and expected to grow in second half. Team focused on strengthening commercial execution and innovation pipelines Q: Free cash flow evolution in 2026 A: Expect modest improvement driven by profitability growth, working capital management, lower interest expense, and lower incentive comp payout. Reg G costs and working capital timing issues affected 2025 free cash flow, but 2026 focus on cash flow improvement Q: R&D reinvigoration and innovation metrics A: Invested $100,000,000 in 2025 in innovation capabilities. Making progress across Scent, Health and Bioscience, and Taste innovation pipelines, with benefits expected in second half 2026 and 2027 Q: Taste segment North America growth and margin drivers A: North America had high single digit growth due to new wins. Margin gains driven by favorable net pricing, cost discipline, productivity, and favorable mix of volume and price Q: GLP-1 theme impact on demand A: International Flavors & Fragrances Inc. working with customers on GLP-1 related products, seeing growth in Taste and Food Biosciences segments due to GLP-1 dynamics Q: Cost inflation outlook for 2026 A: Expect modest input cost inflation. Team collaborating with customers to mitigate, recovering through reformulation, productivity, and pricing. Productivity embedded in plan to offset cost pressures Q: Destocking risk and outlook range A: Destocking risk built into guidance. Range reflects consideration of market dynamics, innovation, and productivity. Second half expected to improve as innovation kicks in Q: Pivot to growth mode post Food Ingredients sale A: Focus on Scent, Taste, and Health and Biosciences segments, which are R&D and innovation heavy. Strong team, commercial and innovation pipelines, and healthy Health and Biosciences business with biotechnology capabilities driving future growth Q: Food Ingredients EBITDA and outlook A: Fourth quarter not as expected, but first quarter off to solid start. Expect top line growth in 2026 with continued strong EBITDA growth. Tax basis considerations in sale process to maximize value for shareholders Q: H&B segment investment and outlook A: Still investing in H&B. Health business had challenges in North America, but new leadership and strong team in place. Expected to start growing again in 2027 with improved execution